Zelluna Asa · OSL:ZLNA
Zelluna Asa — Ultimovacs — Q3 2024 Earnings Presentation
17 slides from Zelluna Asa's earnings presentation, Nov 6, 2024
Slide 1: Third Quarter 2024 Business Update and Financial Results
Third Quarter 2024 Business Update and Financial Results Ultimovacs ASA, November 6, 2024 Carlos de Sousa, CEO / Jens Bjørheim, CMO / Hans Vassgård Eid, CFO
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Ultimovacs ASA (“Ultimovacs” or the expressed or implied by the forward-looking statements contained in this “Company”) for information purposes only and does not constitute an offer to presentation. Given these risks, uncertainties and other factors
Slide 3: Contents
Contents Introduction 01 Clinical update UV1 02 Novel Drug Conjugation Platform 03 Financial update 04 Newsflow 3
Slide 4: Third quarter 2024 – Highlights
Third quarter 2024 – Highlights • Despite disappointing results from INITIUM and FOCUS, we are still committed to bringing UV1 across the next important data point, the DOVACC readout • DOVACC continues to have a good inclusion of patients – topline readout expected H1 2025 • As of September 2024, r
Slide 5: Clinical update UV1
@ultimovacs 01 Clinical update UV1
Slide 6: Investigating UV1 across multiple cancer indications and combinations
Investigating UV1 across cancer multiple indications and combinations Phase II Phase I Indication Combination Randomized Contributors Single-arm trials controlled trials Malignant Ipilimumab INITIUM N=156 melanoma Nivolumab Ultimovacs Malignant sponsored Pembrolizumab UV1-103 N=30 melanoma trials Ma
Slide 7: UV1 Clinical Trials
UV1 Clinical Trials • FOCUS results were published in the preprint platform medRxiv, October 24, 2024: ’UV1 cancer vaccine in pembrolizumab-treated patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma: results from the randomized phase 2 FOCUS trial. • DOVACC (o
Slide 8: Novel Drug Conjugation Platform
02 Novel Drug Conjugation Platform
Slide 9: Novel Drug Conjugation Platform
Novel Drug Conjugation Platform • We are continuing our evaluation of a novel conjugation technology, originally developed to expand our vaccine pipeline • This innovative technology is the result of years of dedicated research and development by our Research and CMC teams • Designed with flexibilit
Slide 10: Financial update
@ultimovacs O03 Financial update
Slide 11: Q3 2024 Key Financials
Q3 2024 Key Financials Cash and liquidity • MNOK 131/MUSD 12 in cash by end of Q3 2024 • Activity level prioritization and operational adjustments are implemented to sustain the financial runway, including a workforce reduction of approximately 40% • Additional cash preservation opportunities have b
Slide 12: P&L and Cash
P&L and Cash Comments Key financials per Q3-2024 - Ultimovacs Group Payroll expenses NOK (000) Q3-23 Q3-24 YTD23 YTD24 FY23 • Due to significant volatility in the company share price in Q1-2024 and Total revenues - - - - - Q2/Q3-2023, which affects the share option costs, total payroll Payroll and p
Slide 13: Quarterly operating cash flow
Quarterly operating cash flow Comments NOK (000) – Negative amounts • The operating cash-flow in Q3 2024 was approximately MNOK -42, differing from EBIT of MNOK -26 primarily due to changes in working capital. • Continued quarterly variations should be expected. It is, however, expected that the cas
Slide 14: Quarterly overview P&L and Cash
Quarterly overview P&L and Cash Key financials per Q3-2024 - Ultimovacs Group NOK (000) Q1-23 Q2-23 Q3-23 Q4-23 Q1-24 Q2-24 Q3-24 Total revenues - - - - - - - Payroll and payroll related expenses 21 002 4 359 24 518 25 251 -2 425 13 708 11 839 - Pa yrol l expens es not i ncl . option cos ts a nd gra
Slide 15: Newsflow
@ultimovacs 03 Newsflow
Slide 16: Newsflow and milestones
Newsflow and milestones UV1 TRIALS/OTHER PIPELINE 2024 2025 Malignant melanoma 4-yr OS Total Phase I: UV1-103 Q2 2024 Malignant melanoma Topline result Phase II: INITIUM March 2024 Malignant pleural Updated at ESMO mesothelioma September 2024 Phase II: NIPU Head and neck cancer Topline results Phase
Slide 17: Q&A
@ultimovacs Q&A